Last reviewed · How we verify
Centocor Ortho Biotech Services, L.L.C. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| infliximab infusion; AZA placebo caps | infliximab infusion; AZA placebo caps | phase 3 | TNF-alpha inhibitor | TNF-alpha | Immunology | |
| infliximab, etanercept | infliximab, etanercept | phase 3 |
Therapeutic area mix
- Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AbbVie (prior sponsor, Abbott) · 1 shared drug class
- Abbott · 1 shared drug class
- Altuğ Güner · 1 shared drug class
- Alvotech Swiss AG · 1 shared drug class
- Asan Medical Center · 1 shared drug class
- Assistance Publique Hopitaux De Marseille · 1 shared drug class
- Bio-Thera Solutions · 1 shared drug class
- ASIS Corporation · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Centocor Ortho Biotech Services, L.L.C.:
- Centocor Ortho Biotech Services, L.L.C. pipeline updates — RSS
- Centocor Ortho Biotech Services, L.L.C. pipeline updates — Atom
- Centocor Ortho Biotech Services, L.L.C. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Centocor Ortho Biotech Services, L.L.C. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centocor-ortho-biotech-services-l-l-c. Accessed 2026-05-17.